definiens: means a second therapeutic Indication having an organ tumor origin different than that of the Indic ation for which prior Regulatory Approval was obtai ned in the applicable territory . Further, with respect to mile stone events ( 1 ) through ( 2 ), inclusive, in the abo ve table, the applicable Clinical Trial must be a Clinical Trial designed such that the results thereof meet the req uirements to be included, or are included, in an NDA in the Unit ed States . In the event a Phase 2 Clinical Trial is deemed a Phase 3 Clinical Trial pursuant to Section 1.71, th e milestone payment for milestone event ( 1 ), in the above table, shall be paid upon FPFV, and the milestone p ayment for milestone event ( 2 ) shall be paid upon a cceptance of filing for Regulatory Approval after the complet ion of such Clinical Trial for the applicable Licen sed Product comprising or containing a Development Candidate